Cargando…

A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio

Background: Nodal status and tumor site are prognostic factors for resectable pancreatic ductal adenocarcinoma (PDAC). Parameters for nodal status are diverse, and the number of examined lymph nodes (eNs) needed for good prognosis are uncertain. We try to modify staging system of resectable PDAC wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yunda, Chen, Zhenxin, Chen, Luohai, He, Chaobin, Huang, Xin, Duan, Fangting, Wang, Jun, Lao, Xiangming, Li, Shengping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171033/
https://www.ncbi.nlm.nih.gov/pubmed/30310507
http://dx.doi.org/10.7150/jca.26187
_version_ 1783360723118718976
author Song, Yunda
Chen, Zhenxin
Chen, Luohai
He, Chaobin
Huang, Xin
Duan, Fangting
Wang, Jun
Lao, Xiangming
Li, Shengping
author_facet Song, Yunda
Chen, Zhenxin
Chen, Luohai
He, Chaobin
Huang, Xin
Duan, Fangting
Wang, Jun
Lao, Xiangming
Li, Shengping
author_sort Song, Yunda
collection PubMed
description Background: Nodal status and tumor site are prognostic factors for resectable pancreatic ductal adenocarcinoma (PDAC). Parameters for nodal status are diverse, and the number of examined lymph nodes (eNs) needed for good prognosis are uncertain. We try to modify staging system of resectable PDAC with parameters mentioned above by recursive partitioning analysis. Methods: Patients from the Surveillance, Epidemiology, and End Results (SEER) database were divided into training cohort and internal validation cohort, randomly. PDAC patients from Sun Yat-sen University Cancer Center were regarded as external validation cohort. The training cohort was used to refine staging model by recursive partitioning analysis, while the internal validation cohort and the external validation cohort were applied to assess discriminatory capacity of staging model. For parameters included in the modified model, their effects were studied. Results: The number of eNs, tumor site and tumor size were risk factors for positive nodal status. Lymph nodes ratio (LNR), tumor site, eNs and T stages of 8(th) the American Joint Committee on Cancer (AJCC) were selected to develop a refined model, dividing patients into 5 groups of different outcomes, preceding 8(th) AJCC classification. Besides, we found that (1) for small PDAC (diameter < 1cm), lymph node metastasis was rarely found; (2) enough eNs were needed to ensure better prognosis of node-negative patients; (3) tumors in the head of pancreas were prone to lymph nodes metastasis; (4) for node-positive patients, LNR was a better nodal parameter compared to positive lymph nodes (pNs). Conclusion: Our improved staging system helps to illuminate the interactions among tumor site, size and eNs.
format Online
Article
Text
id pubmed-6171033
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-61710332018-10-11 A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio Song, Yunda Chen, Zhenxin Chen, Luohai He, Chaobin Huang, Xin Duan, Fangting Wang, Jun Lao, Xiangming Li, Shengping J Cancer Research Paper Background: Nodal status and tumor site are prognostic factors for resectable pancreatic ductal adenocarcinoma (PDAC). Parameters for nodal status are diverse, and the number of examined lymph nodes (eNs) needed for good prognosis are uncertain. We try to modify staging system of resectable PDAC with parameters mentioned above by recursive partitioning analysis. Methods: Patients from the Surveillance, Epidemiology, and End Results (SEER) database were divided into training cohort and internal validation cohort, randomly. PDAC patients from Sun Yat-sen University Cancer Center were regarded as external validation cohort. The training cohort was used to refine staging model by recursive partitioning analysis, while the internal validation cohort and the external validation cohort were applied to assess discriminatory capacity of staging model. For parameters included in the modified model, their effects were studied. Results: The number of eNs, tumor site and tumor size were risk factors for positive nodal status. Lymph nodes ratio (LNR), tumor site, eNs and T stages of 8(th) the American Joint Committee on Cancer (AJCC) were selected to develop a refined model, dividing patients into 5 groups of different outcomes, preceding 8(th) AJCC classification. Besides, we found that (1) for small PDAC (diameter < 1cm), lymph node metastasis was rarely found; (2) enough eNs were needed to ensure better prognosis of node-negative patients; (3) tumors in the head of pancreas were prone to lymph nodes metastasis; (4) for node-positive patients, LNR was a better nodal parameter compared to positive lymph nodes (pNs). Conclusion: Our improved staging system helps to illuminate the interactions among tumor site, size and eNs. Ivyspring International Publisher 2018-09-08 /pmc/articles/PMC6171033/ /pubmed/30310507 http://dx.doi.org/10.7150/jca.26187 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Song, Yunda
Chen, Zhenxin
Chen, Luohai
He, Chaobin
Huang, Xin
Duan, Fangting
Wang, Jun
Lao, Xiangming
Li, Shengping
A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio
title A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio
title_full A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio
title_fullStr A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio
title_full_unstemmed A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio
title_short A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio
title_sort refined staging model for resectable pancreatic ductal adenocarcinoma incorporating examined lymph nodes, location of tumor and positive lymph nodes ratio
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171033/
https://www.ncbi.nlm.nih.gov/pubmed/30310507
http://dx.doi.org/10.7150/jca.26187
work_keys_str_mv AT songyunda arefinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio
AT chenzhenxin arefinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio
AT chenluohai arefinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio
AT hechaobin arefinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio
AT huangxin arefinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio
AT duanfangting arefinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio
AT wangjun arefinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio
AT laoxiangming arefinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio
AT lishengping arefinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio
AT songyunda refinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio
AT chenzhenxin refinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio
AT chenluohai refinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio
AT hechaobin refinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio
AT huangxin refinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio
AT duanfangting refinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio
AT wangjun refinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio
AT laoxiangming refinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio
AT lishengping refinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio